SD Express Delivers New Gigabyte Speeds for SD Memory Cards
19.5.2020 15:00:00 EEST | Business Wire | Press release
The SD Association announced today the SD 8.0 Specification for SD Express memory cards receives even faster transfer speeds by using the popular PCI Express® (PCIe®) 4.0 specification delivering a maximum of nearly 4 gigabytes per second (GB/s) data transfer rate. These full sized cards continue to use the NVMe Express™ (NVMe™) upper layer protocol enabling advanced memory access mechanism. As always SD Express memory cards using SD 8.0 specification maintain backward compatibility.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200519005027/en/
SD Express memory card types (Photo: Business Wire)
“SD Express’ use of even faster PCIe and NVMe architectures to deliver faster transfer speeds creates more opportunities for devices to use SD memory cards,” said Mats Larsson, Senior Market Analyst at Futuresource. “This combination of trusted and well-known technologies makes it easier for future product designs to leverage the benefits of removable storage in new ways.”
SD Express gigabyte speeds bring new storage opportunities for devices with demanding performance levels, across a variety of industries. The cards can move large amounts of data generated by data-intense wireless or wired communication, super-slow motion video, RAW continuous burst mode and 8K video capture and playback, 360 degree cameras/videos, speed hungry applications running on cards and mobile computing devices, ever evolving gaming systems, multi-channel IoT devices and automotive to name a few. SD Express will be offered on SDHC, SDXC and SDUC memory cards.
“By dramatically increasing the speeds for SD Express we’re giving device manufacturers and system developers more storage choices,” said Hiroyuki Sakamoto, SDA president. “SD 8.0 may open even more opportunities for extra high performance solutions using removable memory cards.”
“PCI-SIG® is pleased to see that SDA is continuing to adopt even faster PCIe technology configurations using PCIe 4.0 interface and dual lanes for one of the top leading removable memory cards – SD,” said Al Yanes, PCI-SIG president and chairman. “PCIe specification conformance tests are available today by major test vendors, offering a significant advantage for any new PCIe technology adopter.”
“NVMe is the industry-recognized performance SSD interface from the client to the datacenter, shipping in millions of units,” said Amber Huffman, NVM Express™ Inc. president. “Consumers will benefit by SD Association continuing the adoption of the NVMe base specification for their latest SD Express cards.”
SD Express uses the well-known PCIe 4.0 specification and the latest NVMe specification (up to version 1.4) defined by PCI-SIG and NVM Express, respectively. SD 8.0 specification provides two transfer speed options for SD Express memory cards. The two transfer speeds are accomplished by supporting either PCIe 3.0 x2 or PCIe 4.0 x1 architectures with up to ~2GB/s and with PCIe 4.0 x2 technology with up to 4GB/s. SD Express cards offering PCIe 4.0 x1 architecture use the same form factor as defined for SD 7.0 specification cards with a second row of pins to deliver transfer speeds up to 2 GB/s. SD Express cards supporting dual PCIe lanes (PCIe 3.0 x2 or PCIe 4.0 x2 technologies) have three rows of pins.
The SDA makes adoption of SD Express easy allowing companies to use existing test equipment and saving in product development costs. The SD 8.0 specification continues giving system developers access to PCIe and NVMe technologies, such as Bus Mastering, Multi Queue (without locking mechanism) and Host Memory Buffer.
Two revised white papers, “SD Express Cards with PCIe and NVMe Interfaces,” and “SD Express and microSD Express Memory Cards: The Best Choice for Your Future Product Designs” provide an in-depth look at the opportunities created by SD Express. More information is available on our website.
Visit the SDA Virtual Tradeshow to learn more about SD Express solutions offered by our members.
SD Association
The SD Association is a global ecosystem of nearly 900 technology companies charged with setting interoperable SD standards. The Association encourages the development of consumer electronic, wireless communication, digital imaging and networking products that utilize market-leading SD technology. The SD standard is the number one choice for consumers and has earned more than 80 percent of the memory card market with its reliable interoperability and its easy-to-use format. Today, smart phones, tablets, drones, IoT devices, HDTVs, audio players, automotive systems, computers, digital cameras and digital video cameras feature SD interoperability. For more information about SDA or to join, please visit the Association’s website, https://www.sdcard.org .
SD Logos are trademarks licensed by SD-3C LLC.
PCI-SIG
PCI-SIG is the consortium that owns and manages PCI specifications as open industry standards. The organization defines industry standard I/O (input/output) specifications consistent with the needs of its members. Currently, PCI-SIG is comprised of nearly 800 industry-leading member companies. To learn more about PCI-SIG, and for a list of the Board of Directors, visit www.pcisig.com. PCI Express® is a registered trademark of PCI-SIG.
About NVM Express, Inc.
With more than 100 members, NVM Express is a non-profit organization focused on enabling broad ecosystem adoption of high performance and low latency non-volatile memory (NVM) storage through a standards-based approach. The organization offers an open collection of NVM Express (NVMe™) specifications and information to fully expose the benefits of non-volatile memory in all types of computing environments from mobile to data center. NVMe-based specifications are designed from the ground up to deliver high bandwidth and low latency storage access for current and future NVM technologies. For more information, visit http://www.nvmexpress.org.
PCIe® - PCI Express, is a standard developed by PCI-SIG® and PCIe® is a trademark owned by PCI-SIG.
NVMe™ - NVM ExpressTM, is a standard developed by NVM Express Inc. and NVMe™ is a trademark owned by NVM Express Inc.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200519005027/en/
Contact information
Kevin Schader
SD Association
1.925.275.6670
media@sdcard.org
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom